{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:00:00Z","timestamp":1791644400450,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005940","name":"Dansk Kr\u00e6ftforsknings Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005940","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009512","name":"Agnes og Poul Friis Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009512","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["RR269-A15563"],"award-info":[{"award-number":["RR269-A15563"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R148-A10067-16-S46"],"award-info":[{"award-number":["R148-A10067-16-S46"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15859-w","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:17:23Z","timestamp":1773397043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Demet","family":"\u00d6zcan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Switten","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Alsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Holck","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else","family":"Maae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Louise Holm","family":"Milo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte Vrou","family":"Offersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Tramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"9804","key":"15859_CR1","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","volume":"378","author":"G Collaborative","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019, Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707\u201316.","journal-title":"Lancet"},{"issue":"9935","key":"15859_CR2","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","volume":"383","author":"G Collaborative","year":"2014","unstructured":"Early Breast Cancer Trialists\u2019, Collaborative G, McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127\u201335.","journal-title":"Lancet"},{"issue":"31","key":"15859_CR3","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1200\/JCO.20.01363","volume":"38","author":"BV Offersen","year":"2020","unstructured":"Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, et al. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. J Clin Oncol. 2020;38(31):3615\u201325.","journal-title":"J Clin Oncol"},{"key":"15859_CR4","doi-asserted-by":"publisher","first-page":"111142","DOI":"10.1016\/j.radonc.2025.111142","volume":"212","author":"MS Thomsen","year":"2025","unstructured":"Thomsen MS, Lorenzen EL, Alsner J, Krogh SL, Yates ES, Berg M, et al. Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1. Radiother Oncol. 2025;212:111142.","journal-title":"Radiother Oncol"},{"issue":"6","key":"15859_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","volume":"362","author":"TJ Whelan","year":"2010","unstructured":"Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513\u201320.","journal-title":"N Engl J Med"},{"issue":"9618","key":"15859_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","volume":"371","author":"ST Group","year":"2008","unstructured":"Group ST, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098\u2013107.","journal-title":"Lancet"},{"issue":"4","key":"15859_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","volume":"9","author":"ST Group","year":"2008","unstructured":"Group ST, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331\u201341.","journal-title":"Lancet Oncol"},{"key":"15859_CR8","first-page":"705361","volume":"12","author":"M Zhu","year":"2021","unstructured":"Zhu M, Yang M, Zhang J, Yin Y, Fan X, Zhang Y, et al. Immunogenic Cell Death Induction Ionizing Radiation Front Immunol. 2021;12:705361.","journal-title":"Immunogenic Cell Death Induction Ionizing Radiation Front Immunol"},{"issue":"9","key":"15859_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/stem.3391","volume":"39","author":"M Ruckert","year":"2021","unstructured":"Ruckert M, Flohr AS, Hecht M, Gaipl US. Radiotherapy and the immune system: More than just immune suppression. Stem Cells. 2021;39(9):1155\u201365.","journal-title":"Stem Cells"},{"key":"15859_CR10","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"key":"15859_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fimmu.2017.00231","volume":"8","author":"B Frey","year":"2017","unstructured":"Frey B, Ruckert M, Weber J, Mayr X, Derer A, Lotter M, et al. Hypofractionated Irradiation Has Immune Stimulatory Potential and Induces a Timely Restricted Infiltration of Immune Cells in Colon Cancer Tumors. Front Immunol. 2017;8:231.","journal-title":"Front Immunol"},{"issue":"3","key":"15859_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jamaoncol.2024.5780","volume":"11","author":"I Meattini","year":"2025","unstructured":"Meattini I, Coles CE, Tramm T, Borghesi S, Krug D, Montero A, et al. Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review. JAMA Oncol. 2025;11(3):329\u201339.","journal-title":"JAMA Oncol"},{"issue":"1","key":"15859_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"7","key":"15859_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019;37(7):559\u201369.","journal-title":"J Clin Oncol"},{"key":"15859_CR15","doi-asserted-by":"publisher","first-page":"e2200317","DOI":"10.1200\/PO.22.00317","volume":"7","author":"S Loi","year":"2023","unstructured":"Loi S, Salgado R, Schmid P, Cortes J, Cescon DW, Winer EP, et al. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. JCO Precis Oncol. 2023;7:e2200317.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"15859_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","volume":"5","author":"LA Emens","year":"2019","unstructured":"Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019;5(1):74\u201382.","journal-title":"JAMA Oncol"},{"key":"15859_CR17","doi-asserted-by":"publisher","first-page":"104525","DOI":"10.1016\/j.breast.2025.104525","volume":"83","author":"D \u00d6zcan","year":"2025","unstructured":"\u00d6zcan D, Nielsen AWM, Alsner J, Thorsen LBJ, Overgaard J, Offersen BV, et al. Prognostic value of tumor-infiltrating lymphocytes in irradiated node-positive breast cancer patients. Breast. 2025;83:104525.","journal-title":"Breast"},{"issue":"S1","key":"15859_CR18","doi-asserted-by":"publisher","first-page":"S453","DOI":"10.1016\/S0167-8140(22)02604-4","volume":"170","author":"T Tramm","year":"2022","unstructured":"Tramm T, Nielsen PS, Georgsen JB, Overgaard J, Alsner J. CD8 positive cells indicate gain of postmastectomy radiotherapy: a study of the DBCG82bc cohort. Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol. 2022;170(S1):S453\u2013S.","journal-title":"Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol"},{"issue":"2","key":"15859_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/0284186X.2021.1989629","volume":"61","author":"T Tramm","year":"2022","unstructured":"Tramm T, Vinter H, Vahl P, \u00d6zcan D, Alsner J, Overgaard J. Tumor-infiltrating lymphocytes predict improved overall survival after post-mastectomy radiotherapy: a study of the randomized DBCG82bc cohort. Acta Oncol. 2022;61(2):153\u201362.","journal-title":"Acta Oncol"},{"issue":"14","key":"15859_CR20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1200\/JCO.18.02157","volume":"37","author":"A Kovacs","year":"2019","unstructured":"Kovacs A, Stenmark Tullberg A, Werner Ronnerman E, Holmberg E, Hartman L, Sjostrom M, et al. Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial. J Clin Oncol. 2019;37(14):1179\u201387.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15859_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-20-3299","volume":"27","author":"A Stenmark Tullberg","year":"2021","unstructured":"Stenmark Tullberg A, Puttonen HAJ, Sjostrom M, Holmberg E, Chang SL, Feng FY, et al. Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial. Clin Cancer Res. 2021;27(3):749\u201358.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"15859_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0895-4356(99)00102-X","volume":"52","author":"WE Barlow","year":"1999","unstructured":"Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52(12):1165\u201372.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"15859_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/EDE.0000000000001469","volume":"33","author":"KM O\u2019Brien","year":"2022","unstructured":"O\u2019Brien KM, Lawrence KG, Keil AP. The Case for Case-Cohort: An Applied Epidemiologist\u2019s Guide to Reframing Case-Cohort Studies to Improve Usability and Flexibility. Epidemiology. 2022;33(3):354\u201361.","journal-title":"Epidemiology"},{"issue":"2","key":"15859_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259\u201371.","journal-title":"Ann Oncol"},{"issue":"16","key":"15859_CR25","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784\u201395.","journal-title":"J Clin Oncol"},{"issue":"31","key":"15859_CR26","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997\u20134013.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15859_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118\u201345.","journal-title":"J Clin Oncol"},{"issue":"7","key":"15859_CR28","first-page":"1107","volume":"58","author":"K Baker","year":"2011","unstructured":"Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD. Prognostic significance of CD8\u2009+\u2009T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology. 2011;58(7):1107\u201316.","journal-title":"Histopathology"},{"issue":"10","key":"15859_CR29","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","volume":"2","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol. 2016;2(10):1354\u201360.","journal-title":"JAMA Oncol"},{"issue":"4","key":"15859_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3109\/0284186X.2013.874573","volume":"53","author":"P Christiansen","year":"2014","unstructured":"Christiansen P, Vejborg I, Kroman N, Holten I, Garne JP, Vedsted P, et al. Position paper: breast cancer screening, diagnosis, and treatment in Denmark. Acta Oncol. 2014;53(4):433\u201344.","journal-title":"Acta Oncol"},{"issue":"8","key":"15859_CR31","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","volume":"25","author":"HR Ali","year":"2014","unstructured":"Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association between CD8\u2009+\u2009T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536\u201343.","journal-title":"Ann Oncol"},{"issue":"15","key":"15859_CR32","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","volume":"29","author":"SM Mahmoud","year":"2011","unstructured":"Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8\u2009+\u2009lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949\u201355.","journal-title":"J Clin Oncol"},{"issue":"9","key":"15859_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","volume":"33","author":"C Denkert","year":"2015","unstructured":"Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983\u201391.","journal-title":"J Clin Oncol"},{"key":"15859_CR34","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/1471-2407-12-306","volume":"12","author":"C Medrek","year":"2012","unstructured":"Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306.","journal-title":"BMC Cancer"},{"issue":"18","key":"15859_CR35","doi-asserted-by":"publisher","first-page":"30576","DOI":"10.18632\/oncotarget.15736","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Qu J, Sun Y, Wang J, Liu X, Wang F, et al. Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget. 2017;8(18):30576\u201386.","journal-title":"Oncotarget"},{"issue":"34","key":"15859_CR36","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","volume":"24","author":"GJ Bates","year":"2006","unstructured":"Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15859_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/bjc.2012.524","volume":"108","author":"NR West","year":"2013","unstructured":"West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013;108(1):155\u201362.","journal-title":"Br J Cancer"},{"issue":"5","key":"15859_CR38","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell. 2018;174(5):1293\u2013308. e36.","journal-title":"Cell"},{"issue":"3","key":"15859_CR39","doi-asserted-by":"publisher","first-page":"e1395996","DOI":"10.1080\/2162402X.2017.1395996","volume":"7","author":"M Morisada","year":"2018","unstructured":"Morisada M, Clavijo PE, Moore E, Sun L, Chamberlin M, Van Waes C, et al. PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. Oncoimmunology. 2018;7(3):e1395996.","journal-title":"Oncoimmunology"},{"issue":"17","key":"15859_CR40","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379\u201388.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15859_CR41","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1038\/s41467-019-11906-2","volume":"10","author":"A Arina","year":"2019","unstructured":"Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, et al. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019;10(1):3959.","journal-title":"Nat Commun"},{"issue":"4","key":"15859_CR42","doi-asserted-by":"publisher","first-page":"115566","DOI":"10.1016\/j.celrep.2025.115566","volume":"44","author":"H Koksal","year":"2025","unstructured":"Koksal H, Herbst M, Perreira P, Nater M, Regli N, Boudjeniba C, et al. Pre-existing intratumoral stem-like CD8(+) T cells drive radiotherapy-induced tumor immunity. Cell Rep. 2025;44(4):115566.","journal-title":"Cell Rep"},{"issue":"1","key":"15859_CR43","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl D, Martens JWM, Timmermans M, Smid M, Trapman-Jansen AM, Foekens R, et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. 2021;12(1):5668.","journal-title":"Nat Commun"},{"key":"15859_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41523-020-0156-0","volume":"6","author":"Z Kos","year":"2020","unstructured":"Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020;6:17.","journal-title":"NPJ Breast Cancer"},{"issue":"16","key":"15859_CR45","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180\u20134.","journal-title":"J Natl Cancer Inst"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15859-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15859-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15859-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:02:59Z","timestamp":1776229379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15859-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15859"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15859-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by The Central Denmark Region Committees on Health Research Ethics (journal no. 1-10-72-286-21), The Danish Data Protection Agency (journal no. 2022-522-0408), and registered in the Central Denmark Region\u2019s internal list of research projects (case no. 1-16-02-323-21). The reporting follows Recommendation for Tumor Marker Prognostic Studies criteria [\n                      \n                      ], and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to inclusion in the original randomized DBCG HYPO trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Trine Tramm reports a relationship with AstraZeneca that includes: speaking and lecture fees. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"480"}}